• Consensus Rating: Moderate Buy
  • Consensus Price Target: $27.50
  • Forecasted Upside: 2,031.78%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.29
▲ +0.25 (24.04%)

This chart shows the closing price for DRRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DURECT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DRRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DRRX

Analyst Price Target is $27.50
▲ +2,031.78% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for DURECT in the last 3 months. The average price target is $27.50, with a high forecast of $41.00 and a low forecast of $5.00. The average price target represents a 2,031.78% upside from the last price of $1.29.

This chart shows the closing price for DRRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in DURECT. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024HC WainwrightReiterated RatingNeutralLow
4/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$5.00Low
3/28/2024HC WainwrightReiterated RatingNeutralLow
11/9/2023JonestradingReiterated RatingBuy ➝ Hold$37.00Low
11/7/2023HC WainwrightDowngradeBuy ➝ NeutralLow
9/14/2023Northland SecuritiesInitiated CoverageOutperformLow
8/10/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$44.00 ➝ $41.00N/A
8/10/2023HC WainwrightLower TargetBuy ➝ Buy$32.00 ➝ $27.00N/A
4/11/2023HC WainwrightReiterated RatingBuy$32.00Low
3/14/2023JonestradingInitiated CoverageBuy$37.00Low
3/8/2023Cantor FitzgeraldBoost Target$37.00 ➝ $44.00Low
3/8/2023HC WainwrightLower TargetBuy$35.00 ➝ $32.00Low
12/7/2022OppenheimerBoost Target$6.00 ➝ $32.00Low
11/3/2021Cantor FitzgeraldReiterated RatingOverweightLow
5/5/2021HC WainwrightReiterated RatingBuy$60.00High
2/3/2021Chardan CapitalBoost TargetBuy$70.00 ➝ $80.00High
11/26/2020Chardan CapitalReiterated RatingBuy$70.00Low
10/30/2020Chardan CapitalInitiated CoverageBuy$70.00Medium
10/12/2020Roth CapitalInitiated CoverageBuy$70.00Low
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
7/30/2020OppenheimerInitiated CoverageOutperform$70.00High
6/29/2020B. RileyReiterated RatingBuy$50.00High
5/27/2020HC WainwrightBoost TargetBuy$55.00 ➝ $60.00High
5/26/2020B. RileyReiterated RatingBuy$50.00Medium
5/12/2020B. RileyReiterated RatingBuy$50.00High
5/12/2020HC WainwrightReiterated RatingBuy$55.00Medium
3/4/2020B. RileyReiterated RatingBuy$50.00High
1/31/2020B. RileyInitiated CoverageBuy$50.00Medium
1/22/2020Craig HallumInitiated CoverageBuyMedium
1/3/2020HC WainwrightReiterated RatingBuy$55.00High
11/18/2019Cantor FitzgeraldInitiated CoverageBuy$50.00Low
10/17/2019Cantor FitzgeraldReiterated RatingOverweightHigh
9/18/2019HC WainwrightSet TargetBuy$35.00Low
9/18/2019Stifel NicolausBoost TargetHold$15.00 ➝ $21.00Low
9/10/2019HC WainwrightReiterated RatingBuy$35.00High
9/6/2019Cantor FitzgeraldInitiated CoverageOverweight$50.00High
7/19/2019HC WainwrightSet TargetBuy$40.00Low
(Data available from 5/22/2019 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/25/2023
  • 0 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
11/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/23/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/22/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2024

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
DURECT logo
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Read More

Today's Range

Now: $1.29
Low: $1.01
High: $1.33

50 Day Range

MA: $1.04
Low: $0.77
High: $1.37

52 Week Range

Now: $1.29
Low: $0.47
High: $7.46

Volume

1,846,913 shs

Average Volume

111,051 shs

Market Capitalization

$40.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of DURECT?

The following equities research analysts have issued reports on DURECT in the last twelve months: Cantor Fitzgerald, HC Wainwright, Jonestrading, Northland Securities, Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for DRRX.

What is the current price target for DURECT?

4 Wall Street analysts have set twelve-month price targets for DURECT in the last year. Their average twelve-month price target is $27.50, suggesting a possible upside of 2,031.8%. Cantor Fitzgerald has the highest price target set, predicting DRRX will reach $41.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $5.00 for DURECT in the next year.
View the latest price targets for DRRX.

What is the current consensus analyst rating for DURECT?

DURECT currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DRRX.

What other companies compete with DURECT?

How do I contact DURECT's investor relations team?

DURECT's physical mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company's listed phone number is (408) 777-1417 and its investor relations email address is [email protected]. The official website for DURECT is www.durect.com. Learn More about contacing DURECT investor relations.